TABOMEDEX BIOSCIENCES, INC.
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes. They mainly study the mechanism of action of MK2 and achieve the effect of controlling blood glucose level by inhibiting MK2, namely inhibiting the effect of downstream avtivating enzymes.
TABOMEDEX BIOSCIENCES, INC.
Industry:
Biotechnology Health Care Medical
Founded:
2013-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.tabomedex.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
5 M USD
Technology used in webpage:
Euro Squarespace Hosted
Similar Organizations
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
Viva BioInnovator
Viva BioInnovator investment in Series A - Tabomedex Biosciences, Inc.
JMCR Partners
JMCR Partners investment in Series A - Tabomedex Biosciences, Inc.
Viva Ventures Biotech Fund
Viva Ventures Biotech Fund investment in Series A - Tabomedex Biosciences, Inc.
Official Site Inspections
http://www.tabomedex.com Semrush global rank: 9.07 M Semrush visits lastest month: 445
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Tabomedex Biosciences, Inc."
Tabomedex Biosciences, Inc. - Crunchbase Company …
Organization. Tabomedex Biosciences, Inc. Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Tabomedex focuses on the R&D of new drugs related to type 2 diabetes. ...See details»
Tabomedex Company Profile 2024: Valuation, Investors
Tabomedex General Information Description. Operator of a novel therapeutics company intended to work on research and development of new drugs related to type 2 diabetes. The company is …See details»
OUR TEAM - Tabomedex
Ira tabas, phD Dr. Tabas is the Richard J. Stock Professor of Medicine and Cell Biology at . Columbia University. His research focuses on (1) molecular-cellular mechanismsSee details»
Tabomedex - Products, Competitors, Financials, Employees, …
Tabomedex Biosciences is a company focused on biomedical research in the healthcare sector. Use the CB Insights Platform to explore Tabomedex's full profile. Tabomedex - Products, …See details»
Tabomedex Biosciences, Inc. - Funding, Financials ... - Crunchbase
Tabomedex Biosciences, Inc. is funded by 3 investors. Viva BioInnovator and JMCR Partners are the most recent investors. Unlock for free . ... How much funding has this organization raised …See details»
Tabomedex Biosciences - Company Profile - Tracxn
Oct 31, 2024 Tabomedex Biosciences - Developer of therapies for treating diabetes. Raised funding over 1 round from 2 investors. Founded by Ira Tabas in the year 2014. Tabomedex …See details»
Tabomedex Biosciences, Inc. - Contacts, Employees, Board …
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes.See details»
Tabomedex Biosciences - Overview, News & Similar companies
Tabomedex Biosciences LLC is a company that operates in the Biotechnology industry. It employs 6-10 people and has $0M-$1M of revenue. The company is headquartered in …See details»
Tabomedex Biosciences, Inc. - Biotechnology - Apollo.io
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes. They mainly study the mechanism of action of MK2 and achieve the effect of controlling blood glucose level by …See details»
Tabomedex Biosciences, Inc. - Drug pipelines, Patents ... - Patsnap
100 Deals associated with Tabomedex Biosciences, Inc. Login to view more data. 100 Translational Medicine associated with ... Pipeline. Pipeline Snapshot as of 25 Nov 2024. The …See details»
Tabomedex BioSciences - Viva BioInnovator
Tabomedex is developing new mechanism with an allosteric kinase inhibitor for diabetes treatment. Links. About us Portfolio Team News Contact Us. Our Address. Viva BioInnovator. …See details»
Ira Tabas, MD, PhD, Columbia University
In both the atherosclerosis and metabolism areas, there is strong emphasis on therapeutic translation. In this context, Dr. Tabas is co-founder of Tabomedex Biosciences, LLC, which is …See details»
Treatment of Obese Insulin-Resistant Mice With an Allosteric …
Jun 11, 2015 L.O., B.H., M.H.S.-W., and I.T. are in the group of cofounders of Tabomedex Biosciences, LLC, which is developing inhibitors for the treatment of type 2 diabetes. No other …See details»
Tabomedex Biosciences, Inc. - Tech Stack, Apps, Patents
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes.See details»
TBX-1 - Drug Targets, Indications, Patents - Synapse
TBX-1: a MAPKAPK2 inhibitors Drug, Initially developed by Columbia University Irving Medical Center, Now, its global highest R&D status is Preclinical, Mechanism: MAPKAPK2 …See details»
Allosteric MAPKAPK2 Inhibitors Improve Plaque Stability in …
Jan 12, 2021 Atherosclerotic vascular disease resulting from unstable plaques is the leading cause of morbidity and mortality in subjects with type 2 diabetes (T2D), and thus a major …See details»
(PDF) Allosteric MAPKAPK2 Inhibitors Improve Plaque Stability in ...
Jan 12, 2021 2 Tabomedex Biosciences, Boxford, MA . 3 Department of Pathol ogy and Cell Biology, Columbia University I rving M edical Center, New York, NY. 4 Department of …See details»
TBX-2 - Drug Targets, Indications, Patents - Synapse
TBX-2: a MAPKAPK2 inhibitors Drug, Initially developed by Columbia University Irving Medical Center, Now, its global highest R&D status is Preclinical, Mechanism: MAPKAPK2 …See details»
Treatment of Obese Insulin-Resistant Mice With an Allosteric
The prevalence of obesity-induced type 2 diabetes (T2D) is increasing worldwide, and new treatment strategies are needed. We recently discovered that obesity activates a previously …See details»